TRIAL DETAIL

Evaluate the Efficacy of AMG 706 to Treat Advanced Gastrointestinal Stromal Tumors (Japan)

Drug:
Trial Name:
Evaluate the Efficacy of AMG 706 to Treat Advanced Gastrointestinal Stromal Tumors (Japan)
NCT#:
Conditions:
Advanced Gastrointestinal Stromal Tumor
Status:
Completed
Phase:
2
Start Date 11/01/2005
Age of Trial (yrs) 18.4
Treatment Phase:
Gleevec-resistant
Drug Category:
KIT/PDGFRA inhibitor VEGFR inhibitor (TKI)
Strategy:
Block KIT
Trial Type:
Specifically GIST and only GIST
Other Protocol IDs:
20050129
Sponsor:
Amgen Inc.
Patient Contact:
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Oral
Trial Notes:
PURPOSE: Motesanib (AMG 706) is a multitargeted anticancer agent with an inhibitory action on the human vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and the cellular stem-cell factor receptor (KIT). The aim of this single-arm phase II clinical study was to assess the efficacy and safety of single-agent motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate.

Trial Links

Trial Results

 
 
 

Drug Information

AMG 706 - Cancer Research - Full text
 
Motesanib in thyroid cancer - NEJM
 
The Molecular Basis of Class Side Effects Due to Treatment with Inhibitors of the VEGF/VEGFR Pathway
 
Amgen pipeline-Motesanib
 
Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors. (full text article)
 

Trial Sites

Name
Address
City
State
Zip
Country